Aligos Therapeutics, Inc.
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
ALGS | US
Overview
Corporate Details
- ISIN(s):
- US01626L2043
- LEI:
- Country:
- United States of America
- Address:
- ONE CORPORATE DR., 2ND FLOOR, 94080 SOUTH SAN FRANCISCO
- Website:
- https://www.aligos.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, best-in-class therapies for liver and viral diseases. Leveraging deep expertise in medicinal chemistry, biology, and virology, the company builds a differentiated pipeline of purpose-built drugs with enhanced pharmacologic properties to address significant unmet medical needs. The company's development pipeline features Pevifoscorvir, an oral small molecule capsid assembly modulator for chronic hepatitis B (CHB), and ALG-055009, an oral small molecule thyroid hormone receptor beta (THR-β) agonist for metabolic dysfunction-associated steatohepatitis (MASH).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Aligos Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Aligos Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Aligos Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
